BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Bio-Techne Corp. Declares Dividend

  The quarterly dividend will be payable November 24, 2017 to all common shareholders of record on November 10, 2017.

  October 31, 2017

   · 

  1 min read
• Drug Development

  MabVax Therapeutics Provides Update on the MVT-5873 Phase I Clinical Program and Expansion of Preclinical Development Pipeline at the AACR-NCI-EORTC International Conference

  Three posters were presented by Paul W. Maffuid, Ph.D., Executive VP of R&D, outlining important progress in the Company’s lead fully human antibody programs which included HuMab-5B1 currently in Phase I clinical development for the treatment of pancreatic cancer and other CA19-9 positive malignancies.

  October 31, 2017

   · 

  6 min read
• Policy

  Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia

  The EC’s approval follows a positive opinion in July 2017 from the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP).

  October 31, 2017

   · 

  5 min read
• Biotech Beach

  Inhibrx Wins CARB-X Award of Up to $6M To Accelerate Development of its Novel Antibody, INBRX-111, to Treat Pseudomonas Infections

  InhibRx announced today a significant collaboration with CARB-X.

  October 31, 2017

   · 

  3 min read
• Drug Development

  Agile Therapeutics Presents Additional Phase III SECURE Trial Results for Twirla at the ASRM Scientific Congress Expo 2017

  Agile Therapeutics today announced additional data from its Phase III SECURE trial of Twirla which showed women experienced mean decreases in length of bleeding and spotting episodes.

  October 31, 2017

   · 

  6 min read
• Business

  InfuSystem to Issue Third Quarter 2017 Financial Results on Friday, November 10, 2017, Before the Market Opens

  The Company will also conduct a conference call for all interested investors on Friday, November 10, 2017, at 11:00 a.m.

  October 31, 2017

   · 

  1 min read
• Business

  Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2018

  Array BioPharma today reported results for its first quarter of fiscal 2018 and provided an update on the progress of its key clinical development programs.

  October 31, 2017

   · 

  24 min read
• Drug Development

  Impel NeuroPharma Announces First Patient Dosed in Phase I Clinical Trial of INP104 for Treatment of Acute Migraine Headache

  The Phase I trial will investigate the comparative bioavailability of INP104 versus two approved DHE formulations.

  October 31, 2017

   · 

  3 min read
• BGI’s MGI Tech Launches Two New NGS Platforms

  MGI Tech launched two new next generation genetic sequencers, MGISEQ-2000 and MGISEQ-200, at the 12th International Conference on Genomics in Shenzhen.

  October 31, 2017

   · 

  3 min read
• 

  Policy

  Novartis Submits Application to FDA for Kymriah (Tisagenlecleucel) in Adult Patients With R/R DLBCL, Seeking Second Indication for First-Ever FDA Approved CAR-T Therapy

  If approved, this would be the second indication for Kymriah.

  October 31, 2017

   · 

  13 min read